A Research Study to Look Into the Long-term Effect on Weight Loss of CagriSema in People With Obesity
Public ClinicalTrials.gov record NCT06780449. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Long-term Efficacy and Safety of Cagrilintide s.c. 2.4 mg in Combination With Semaglutide s.c. 2.4 mg (CagriSema 2.4 mg/2.4 mg) Once Weekly Versus Placebo in Participants With Obesity
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study will look at how well CagriSema helps people with obesity lose weight compared to a "dummy medicine". CagriSema is a new medicine developed by Novo Nordisk. CagriSema cannot yet be prescribed by doctors. The study has two parts: First part is called the main phase and will last for 2 years, and second part is called the extension phase and will last for 1 year. In the main phase participants will either get CagriSema or "dummy medicine". Which treatment participants get is decided by chance and is not known by participants or the study doctor. In the extension phase participants will get either CagriSema or slowly reduce participants dose of CagriSema if participants had CagriSema in the main phase. Which treatment participants get is decided by chance and is not known by participants or the study doctor in both phases. If participants had "dummy medicine" in the main phase, participants will get CagriSema in the extension phase. Like all medicines, the study medicine may have side effects.
Study identification
- NCT ID
- NCT06780449
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 400 participants
Conditions and interventions
Conditions
Interventions
- Cagrilintide Drug
- Semaglutide Drug
- Placebo cagrilintide Drug
- Placebo semaglutide Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 9, 2025
- Primary completion
- Aug 27, 2028
- Completion
- Oct 30, 2028
- Last update posted
- Jan 19, 2026
2025 – 2028
United States locations
- U.S. sites
- 10
- U.S. states
- 9
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Valley Clinical Trials | Covina | California | 91723 | — |
| Diablo Clinical Research, Inc. | Walnut Creek | California | 94598 | — |
| Yale University School Of Medicine | New Haven | Connecticut | 06519 | — |
| East West Medical Research Institute_Honolulu | Honolulu | Hawaii | 96814 | — |
| L-MARC Research Center | Louisville | Kentucky | 40213 | — |
| StudyMetrix Research LLC | City of Saint Peters | Missouri | 63303 | — |
| Spartanburg Medical Research | Spartanburg | South Carolina | 29303 | — |
| Holston Medical Group_Bristol | Bristol | Tennessee | 37620 | — |
| North Texas Endocrine Center | Dallas | Texas | 75231 | — |
| Washington Cntr Weight Mgmt | Arlington | Virginia | 22206 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 26 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06780449, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 19, 2026 · Synced Sep 10, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06780449 live on ClinicalTrials.gov.